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Abstract
Background: Hormone therapy is the standard of care for newly diagnosed or recurrent prostate cancers. It uses
anti-androgen agents, castration, or both to eliminate cancer promoting effect of testicular androgen. The p53
tumor suppressor controls a major pathway that can block cell proliferation or induce apoptosis in response to
diverse forms of oncogenic stress. Activation of the p53 pathway in cancer cells expressing wild-type p53 has been
proposed as a novel therapeutic strategy and recently developed MDM2 antagonists, the nutlins, have validated
this in preclinical models of cancer. The crosstalk between p53 and androgen receptor (AR) signaling suggest that
p53 activation could augment antitumor outcome of androgen ablation in prostate cancer. Here, we test this
hypothesis in vitro and in vivo using the MDM2 antagonist, nutlin-3 and the p53 wild-type prostate cancer cell line,
LNCaP.
Results: Using charcoal-stripped serum as a cellular model of androgen deprivation, we show an increased
apoptotic effect of p53 activation by nutlin-3a in the androgen-dependent LNCaP cells and to a lesser extent in
androgen-independent but responsive 22Rv1 cell line. This effect is due, at least in part, to an enhanced
downregulation of AR expression by activated p53. In vivo, androgen deprivation followed by two weeks of nutlin
administration in LNCaP-bearing nude mice led to a greater tumor regression and dramatically increased survival.
Conclusions: Since majority of prostate tumors express wild-type p53, its activation by MDM2 antagonists in
combination with androgen depletion may offer an efficacious new approach to prostate cancer therapy.
Background
Despite advances in diagnostics and treatment, prostate
cancer remains the second leading cause of cancer
deaths in the US. Current treatments attempt to block
cancer cell growth and induce cell death by removing or
inhibiting the androgens that support tumor growth [1].
Surgical (orchiectomy) or chemical (LHRH agonist/
antagonist) castration to eliminate testicular- androgen
can delay clinical progression [2]. Anti-androgens such
as flutamide or the more potent bicalutamide, which
block the hormone-receptor interaction, have also been
shown to improve survival [3-5]. Combined androgen
blockade (CAB) applies both castration and anti-
androgens, or estrogens to maximize the block on
androgens including those produced from the adrenal
gland. However, survival benefit from CAB is rather
controversial and still under scrutiny [1]. Unfortunately,
the majority of prostate cancer patients will eventually
become resistant to one or all of these therapeutic
strategies.
T h em e c h a n i s m sb e h i n dt h er e s i s t a n c et oa n d r o g e n
deprivation are not well understood although existing
experimental evidence suggest that androgen withdrawal
predominantly induces a cessation of cell proliferation
but not overt apoptosis. In vitro studies with LNCaP
cells grown in charcoal-stripped serum to mimic andro-
g e na b l a t i o ns h o wad e c r e a s ein proliferation without
apoptosis [6]. This is unlikely due to ineffective andro-
gen removal because a recent study has indicated that
tissue culture media supplemented with 10% fetal calf
* Correspondence: lyubomir.vassilev@roche.com
† Contributed equally
Discovery Oncology, Roche Research Center, Hoffmann-La Roche Inc., Nutley,
NJ 07110, USA
Tovar et al. Molecular Cancer 2011, 10:49
http://www.molecular-cancer.com/content/10/1/49
© 2011 Tovar et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.serum (FCS) contain castrate levels of testosterone and
the level of androgen is well below serum levels of
castrated males [7]. Normal rat prostate (and likely nor-
mal human prostate gland) respond to androgen abla-
tion with high levels of apoptosis leading to glandular
involution [8-10]. However, in human prostate cancer
cells, the apoptotic response to androgen deprivation is
not as clearly evident. It has been shown that androgen
deprivation induces cell cycle arrest rather than apopto-
sis in three well known androgen-dependent cell lines,
LNCaP, CWR22, and LuCaP-35 in vitro and in vivo
[6,11,12]. Eventually, cell proliferation resumes, leading
to an androgen-independent state in these model sys-
tems in vivo. This makes them a good model to assess
the ability of therapeutics to induce cell death in combi-
nation with androgen ablation. The molecular response
to in vivo androgen withdrawal was studied closely in
the human prostate cancer xenograft model CWR22 in
nude mice. Androgen ablation induced a robust stress
response with an apparent p53-mediated cell cycle arrest
but no p53-dependent apoptosis. Additionally the
increased expression of p53 was only transient [11,13].
Lastly, studies of human tumor samples taken from
patients that have undergone androgen deprivation
show significant decreases in proliferation but minimal
apoptotic index [9,10,14].
The p53 protein is a potent tumor suppressor that can
induce cell cycle arrest or apoptosis in response to var-
ious forms of cellular stress [15]. Under non-stressed
conditions, p53 is tightly controlled by its negative regu-
lator MDM2 via an autoregulatory feedback loop
[16,17]. p53 activates the transcription of the mdm2
gene and in turn MDM2 protein inhibits p53 transcrip-
tional activity. In addition, MDM2 is a p53-specific E3
ligase which targets p53 for ubiquitination and degrada-
tion in the proteasome [18]. As a result of proper func-
tioning of this autoregulatory loop both p53 and MDM2
are kept at low levels. In response to stress, the cellular
levels of p53 increase leading to activation of multiple
target genes and the p53 pathway with its main func-
tions: cell cycle arrest and apoptosis [15,19]. These anti-
tumor consequences make p53 a desirable target for
pharmacological activation [20].
In addition to its role in cell cycle arrest and apopto-
sis, p53 has also been implicated in the regulation of AR
[21]. Although the mechanism by which p53 exerts its
control over AR is not clearly understood, p53 over-
expression has been shown to decrease androgen func-
tion apparently by reduction in the expression of andro-
gen-dependent genes [22,23]. However, this regulation is
quite complex given that at physiological levels p53 may
act to protect androgen signaling [21]. Conversely,
androgen signaling has been found attenuated in etopo-
side-treated LNCaP cells as the stabilized p53 binds to
the AR gene promoter [24]. Hence, p53 could facilitate
the reduction of AR signaling by occupying and compet-
ing for AR promoter. A recent study has also implicated
p53 negative regulator MDM2 in modulation of AR pro-
tein levels by targeting it for ubiquitin-dependent degra-
dation [25].
We have demonstrated that a potent and selective
small-molecule inhibitor of the p53-MDM2 binding,
nutlin-3a, can stabilize p53 and activate the p53 pathway
in a broad panel of wild-type tumor lines including
prostate [26,27]. By disrupting p53-MDM2 regulatory
circuit, nutlin elevates not only p53 but also MDM2, a
transcription target of p53. Although MDM2 is kept
away from p53, nutlin-bound MDM2 retains its E3
ligase activity against itself and possibly other targets. It
has been documented that elevated MDM2 can facilitate
MDMX ubiquitination and degradation in the presence
of nutlin [28]. Therefore, one can expect that nutlin-
induced elevated MDM2 could also facilitate AR degra-
dation and further reduce AR levels when combined
with androgen ablation. Here, we show that activation
of the p53 pathway by nutlin-3a substantially augments
the antitumor effect of androgen ablation. In vitro, com-
bination of nutlin-3a with androgen deprivation in pros-
tate cancer cell lines expressing wild-type p53 led to an
increase in apoptosis over single agent treatments. More
significantly, combination treatment of mice bearing
LNCaP xenografts resulted in frequent complete tumor
regressions and a dramatic increase in lifespan.
Results
Nutlin-3a activates the p53 pathway in LNCaP prostate
cancer cells
To study the combined effect of p53 activation and andro-
gen deprivation, we chose the androgen-depenedent pros-
tate cancer cell line LNCaP as a cellular model. We have
shown previously that nutlin-3a activates p53 and inhibits
the growth of LNCaP cells and xenograft tumors in nude
mice [27]. Incubation of proliferating LNCaP cells with
nutlin-3a for 5 days showed a dose-dependent effect with
EC50 of 0.5 μM (Figure 1A). Western blot analysis follow-
ing 24 h nutlin treatment revealed p53 accumulation and
concurrent increases in its transcriptional targets MDM2
and p21
Waf1/CIP1 (Figure 1B). Additionally, BrdU cell cycle
analysis showed a loss of S-phase and increase of G1 and
G2/M phase fractions consistent with p53-mediated cell
cycle block in G1 and G2 phases (Figure 1C). To assess
the apoptotic activity of nutlin-3a we used the Annexin V
assay. Nutlin showed both a dose-dependant and time-
dependant increase in the apoptotic fraction (Figure 1D).
These results confirm that MDM2 antagonists stabilize
p53 protein in LNCaP cells and effectively activate p53 sig-
naling and the main p53 functions, cell cycle arrest and
apoptosis.
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deprivation further reduces AR levels and enhances
apoptosis
In addition to the androgen-dependent LNCaP cells, two
other prostate cancer cell lines were chosen to investi-
gate the combination effect of androgen ablation and
p53 activation: 22Rv1 and DU145. Wild-type p53
expressing 22Rv1 cells have an androgen responsive AR
but can grow independent of androgen in vivo. DU145
cells that express mutant p53 were used as a negative
control since MDM2 antagonists require wild-type p53
for their cellular activity [26]. Cells were incubated in
media containing either normal serum or charcoal-
stripped serum (CSS) which has been shown to effec-
tively eliminate androgen and thus mimic androgen
ablation [7]. A suboptimal nutlin-3a dose of 5 μMw a s
used (Figure 1D). Cells were also treated with 5 μMo f
the anti-androgen hydroxy-flutamide (FLU) in the pre-
sence of complete or CSS. Western blot analysis of
LNCaP cells revealed that CSS in combination with
nutlin elicits further reduction of AR levels than CSS
alone in LNCaP cells and to a lesser extent in 22Rv1
cells (Figure 2A-B). Both LNCaP and 22Rv1 expressed
full- length AR (110 kDa and 114 kDa respectively),
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Figure 1 Nutlin-3a activates p53 signaling in LNCaP cells. A) Antitumor activity of Nutlin-3a. Cells were incubated with nutlin-3a for 5 days
and cell growth/viability measured by the MTT assay. B) Changes in key proteins. Exponentially proliferating LnCAP cells were treated with 10
μM Nutlin-3a, or DMSO for 20 h and cell lysates were analyzed by Western blotting. C) Nutlin inhibits cell cycle progression. LNCaP cells were
treated with 10 μM nutlin-3a for 20 h and analyzed by BrdU labeling and flow cytometry. Box indicates the S phase compartments. D) Nutlin
induces dose and time-dependent apoptosis in LNCaP cells. Cells were incubated with nutlin-3a at the indicated concentrations and the
percentage of the Annexin V-positive cells was determined. Time-dependant apoptosis was determined at 10 μM concentration.
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AR mRNA levels in LNCaP cells by quantitative PCR
revealed a 2-fold decrease in the presence of nutlin or
CSS but no significant change in the combination (data
not shown). Stabilization of p53 and subsequent
increases in p21 and MDM2 levels were only observed
in the presence of nutlin but not CSS indicating that
CSS does not cause stress-related p53 activation.
Then, we examined the apoptotic response after 48
hour drug treatment (Figure 2). While CSS did not
Figure 2 Combination effect of nutlin and androgen deprivation in vitro. LNCaP (A), 22Rv1 (B), and DU145 cells (C) were exposed to 5 μM
Flutamide (FLU) and/or 5 μM Nutlin-3a in the presence of complete serum or charcoal stripped serum (CSS). Western blotting was used to
monitor protein levels of Androgen receptor (AR) and the Annexin V assay to measure apoptotic response ± SD.
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Page 4 of 11induce apoptosis over the control level in LNCaP cells,
the combination with nutlin enhanced the apoptosis
observed with nutlin alone (Figure 2A). Flutamide did
not show a significant change in apoptosis. However,
the triple combination (Nutlin + CSS + FLU) further
increased the apoptotic index in LNCaP but not in
22Rv1 cells (Figure 2B). As expected, the p53-mutant
and AR-negative line DU145 did not show an increase
in p21 and MDM2. AR levels were also undetectable
and no significant change in apoptotic fractions
observed (Figure 2C).
Bicalutamide (Casodex) enhances apoptotic activity of
Nutlin-3a in LNCaP and 22Rv1 cells
Exponentially growing LNCaP, 22Rv1, and DU145 were
incubated with 10 μM of another clinically used anti-
androgen, Casodex (CDX), and/or 5 μM Nutlin-3a in
the presence of complete serum or CSS. Percent apopto-
sis was determined by Annexin V staining after 48 hours
(Figure 3). Data revealed that combined treatment with
Nutlin-3a and CDX was more effective at inducing
apoptosis than single agent treatments in both LNCaP
and 22Rv1 cells. However, the combination of Nutlin-3a
and CDX was less effective than Nutlin + CSS combina-
tion in LNCaP cells while triple treatment showed slight
improvement over Nutlin + CSS combination. Nutlin +
CDX combination showed a slightly better activity than
Nutlin + CSS in 22Rv1 and triple treatment did not
demonstrate greater effect over dual in this cell line.
AR reduction accounts for the increased apoptotic
activity of nutlin-3a in CSS
To further investigate if the apoptosis enhancing effect
of CSS is due to AR reduction, we depleted AR in
LNCaP cells grown in normal serum using AR-specific
siRNA. Western blotting confirmed the effective reduc-
tion of AR and showed that only in the presence of
nutlin was there stabilization of p53 and activation of its
transcription targets, p21 and MDM2 (Figure 4A). Addi-
tion of nutlin to AR-depleted LNCaP (siRNA-AR) cells
led to a substantial increase in the apoptotic cell fraction
over nutlin alone (Figure 4B). We then combined
siRNA-AR and CSS with or without nutlin (Figure 4C).
Apoptotic fraction of LNCaP cells in CSS + nutlin was
nearly equivalent to the triple combination (CSS +
siRNA-AR + nutlin), implying that CSS effectively
reduces AR levels and that this is the main mechanistic
cause for enhanced apoptotic response.
Nutlin-induced AR reduction does not involve MDM2-
dependant degradation
MDM2 has been shown to serve as an E3 ubiquitin ligase
for p53 and several other proteins, most notably MDMX
[28]. Moreover, AR degradation by Akt has been reported
to require the E3 ligase activity of MDM2 [25]. Since
nutlin treatment leads to a dramatic elevation of MDM2
protein one can expect facilitated degradation of AR, if
nutlin-bound MDM2 can retain its activity against AR as
previously shown with another MDM2 target, MDMX
[28]. To test this possibility, we examined the protein
levels of MDM2 and MDMX in the presence or absence
of nutlin and/or CSS (Figure 5A). Nutlin treatment drama-
tically increased MDM2 levels and led to a significant
reduction of MDMX but did not change AR protein levels.
The reduction of MDMX was due to enhanced protein
degradation since the proteasome inhibitor MG132
restored its levels. These results indicate that either
MDM2 cannot facilitate AR degradation in LNCaP cells
or that it has lost its activity against AR when in complex
with the small-molecule inhibitor nutlin-3a. To distinguish
between these possibilities, we generated a LNCaP cell
clone stably expressing high levels of full length MDM2
protein under a CMV promoter. Western blot analysis
showed significantly reduced levels of MDMX similar to
nutlin-treatment. AR was also reduced but to a lesser
extent. These experiments confirmed the previous obser-
vation that MDM2 protein can affect AR protein levels
[25] and suggest that this ability is likely lost when nutlin-
3a is bound to the MDM2 protein.
Androgen deprivation does not affect nutlin-induced miR-
34 expression
Recently, Rokhin at al. reported that LNCaP cells cul-
tured in androgen-free media and then treated with the
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expression of p53 transcription targets miR-34a and
miR-34c, resulting in inhibition of apoptosis [29]. It has
been shown previously that nutlin activates miR-34(a-c)
expression [30]. Therefore, we examined if the combina-
tion of nutlin and CSS can affect miR-34 levels. Expo-
nentially proliferating LNCaP cells were incubated in
CSS, 5 μM nutlin-3a, or combination of both for 24 h,
and miR-34(a, b and c) levels were measured by quanti-
tive PCR. We found significant induction of all three
miRNA species by nutlin (34a:4.4, 34b:35.8, 34c:36.4
fold average) and less than 2 × fold increase in the pre-
sence of CSS. However, the combination did not signifi-
cantly change the levels of any of the three miR over
nutlin alone (data not shown). These experiments sug-
gest that androgen deprivation does not affect miR-34
induction by non-genotoxic p53 activation.
Nutlin-3a enhances antitumor activity of androgen
deprivation in vivo and substantially increases lifespan of
nude mice
Finally, we examined if androgen ablation combined with
nutlin-3a could enhance anti-tumor activity against estab-
lished human prostate tumor xenografts (Figure 6A). To
this end, pre-castrated nude mice were implanted with
sustained-release testosterone pellets 5 days prior to injec-
tion of LNCaP cells. Tumors were fully established with
an average starting tumor volume of approximately 400
mm
3 in each group. Mice were administered an optimal
oral dose of nutlin-3a at 200 mg/kg twice a day (bid) for
14 days. Others were treated with removal of testosterone
pellets as a model of androgen ablation. Additional mice
were treated with a combination of ablation + nutlin-3a.
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Page 6 of 11Control mice were dosed with vehicle + sham pellet
removal. Nutlin was well tolerated in all groups with no
significant body weight loss in any group throughout the
study. Tumor regressions were observed in all groups rela-
tive to vehicle. Nutlin-treated animals had 6/10 partial
regressions, androgen ablation caused 20/20 partial regres-
sions, and combination of nutlin + ablation yielded 13/20
partial regressions including 7/20 complete regressions
(no complete regressions were observed in the other
groups). At day 42 post tumor cell inoculation (last day of
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Figure 6 Nutlin-3a greatly enhances antitumor activity of androgen deprivation in vivo. A) LNCaP cells were grown subcutaneously in
pre-castrated male athymic nude mice in the presence of testosterone pellets until reaching approximately 400 mm
3 on average. Mice were
administered Nutlin-3a at 200 mg/kg bid (n = 10) or testosterone pellets were removed to simulate androgen ablation (n = 20). Additional mice
were treated with a combination of ablation + Nutlin-3a at 200 mg/kg bid orally for 14 days (n = 20). Control mice were dosed with vehicle for
14 days + sham pellet removal under anesthesia (n = 10). B) PSA levels reflect changes in tumor volume. At day 42, five random mice in each
group were bled and PSA levels ± SD were determined. C) Combination of nutlin and androgen deprivation increases lifespan of mice. After
completion of treatment, mice were monitored for over a year and ILS was calculated by the Kaplan-Meier formula. Survival was calculated using
a cut-off of 1000 mm
3.
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gen (PSA) in serum showed a 68% decrease with nutlin
treatment alone compared to vehicle control (Figure 6B).
Androgen ablation and combination treatment reduced
serum PSA levels 94% and 98%, respectively.
Based on NCI criteria, an increase in lifespan (ILS) of
≥25% is biologically significant [31]. Twice daily dosing
of nutlin-3a produced a 57% ILS and androgen depriva-
tion gave a 167% ILS (Figure 6C). Although the differ-
ence in tumor volume at day 42 between androgen
deprivation and combination treatment was only 6-fold
(Figure 6A), over time, nutlin + androgen deprivation
resulted in a greater than 886% ILS. This was the result
of the majority of regressions never re-growing and the
mice therefore died of perceived natural causes (no
gross signs of primary subcutaneous tumor or metastasis
upon necropsy in all cases). Collectively, our results
demonstrate a clear benefit of administering nutlin-3a in
conjunction with androgen ablation.
Discussion
Although androgen withdrawal/deprivation is the predo-
minant course of treatment for advanced prostate can-
cer, eventually all patients will develop resistance to this
therapy. Moreover, the mechanism underlying hormone
refractory disease progression has yet to be elucidated.
Our in vivo data supports the conclusion that ablation
elicits an impressive yet transient antitumor effect in
concordance with early clinical response. However, akin
to long term clinical results, our xenograft data shows
that over time androgen deprivation does not result in
sustained regressions (Figure 6C). Disappointingly, clini-
cal results also show that most if not all advanced pros-
tate cancers become androgen independent after
surgical or chemical castration [1]. Taken together,
these observations provide credence to the notion that
ablation predominantly acts as an anti-proliferative
rather than strong pro-apoptotic modality [11,14,32].
Further complicating matters is the apparent heteroge-
neity of advanced prostate tumors [33,34]. Taking this
into account, initial anti-androgen therapy may simply
eliminate a modest portion of a genetically-diverse
androgen-dependant tumor cell population and provide
s e l e c t i v ep r e s s u r et ot h er e m a i n i n gm a l i g n a n c yt h a t
favors growth of new or pre-existing androgen-indepen-
dent cell populations [35-37].
Although the requirement for androgen is no longer
necessary in refractory disease the AR can still potenti-
ate tumor growth and survival, thus activity of the AR
remains a focal point of therapy even in advanced stages
of androgen independent prostate cancer [38-40]. It is
also evident that there are numerous mechanisms by
which aberrant androgen signaling occurs in the devel-
opment and progression of prostate cancer. Examples
include AR hypersensitivity via gene amplification,
changes in ligand specificity via mutation, increases in
AR gene expression or androgen biosynthesis, all of
which permit growth advantages in low androgen envir-
onments [37,40]. It is therefore imperative when using
model systems to take into account the cellular milieu
in which the AR exists. The LNCaP line used in this
study for example, harbors the mutation T877A in the
ligand binding domain. The consequence of this muta-
tion is a loss of ligand specificity and promiscuous acti-
vation of AR with progestins, estrogens, adrenal
androgens and surprisingly some anti-androgens.
[37,38,41]. Consistent with published data, the androgen
independent yet responsive 22Rv1 line show two mutant
forms of the AR: a 114-kDa full-length form containing
an exon-3 duplication and a truncated 80 kDa form
which lacks the ligand binding domain ([42] and Figure
2B). In addition, the AR in 22Rv1 cells contains a His
874
to Tyr substitution that also permits stimulation by
adrenal androgens albeit likely through a different
mechanism than the T877A substitution in LNCaP cells
[43]. Nevertheless, it is the AR that appears to be the
principal accomplice in progressing towards complete
androgen-independence [38-40].
Recent evidence suggests that the androgen receptor
can confer cell survival by negatively regulating pro-
apoptotic genes in the p53 pathway [41]. Moreover,
overexpression of wild-type AR in LAPC4 or mutant AR
in LNCaP lines can promote cell survival by inhibiting
p53 mediated apoptosis [44]. Additionally, the potent
androgen Dihydrotestosterone (DHT) has also been
shown to decrease p53 levels and inhibit apoptosis in a
dose dependent manner [45]. Alternatively, AR expres-
sion can be diminished by increased levels of p53 [24].
Highlighting the complex interplay between AR and p53
expression is the observation that physiological levels of
p53 may be necessary to stabilize AR signaling [21].
Interestingly, LNCaP cells cultured in steroid-free media
decreased both p53 protein and mRNA levels equal to
that of treatment with high concentration of DHT.
However, p53 knockdown in LNCaP cells have shown
no change in AR levels regardless of DHT [45]. Taken
together these findings suggest a mutual regulation of
expression between p53 and AR. Therapeutic strategies
aimed at disrupting the delicate cross-talk between AR
and p53 must not only favor p53 expression, but also
potentiate the apoptotic outcome of p53 activation.
Our published [27] and current data demonstrates that
nutlin-3a alone has potent activity in the LNCaP cell line
and in LNCaP xenograft models. As expected, nutlin-3a
effectively activated the p53 pathway indicated by the
increased expression of transcriptional targets, cell cycle
arrest and apoptosis (Figure 1). These changes were not
observed with CSS treatment and support the notion that
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induced p53 activation. It is important to note that media
supplemented with 10% fetal calf serum (FCS) does not
represent normal physiological levels of testosterone but
rather contain levels that are equivalent to that of serum
in adult castrated males, nonetheless, LNCaP cells are
able to maintain ~10 nM intracellular DHT concentra-
tion in 10% FCS by optimizing their AR and androgen
metabolism [7]. Thus LNCaP cultured in CSS is exposed
to testosterone levels significantly lower than that mea-
sured in serum from castrated adult males [7]. Unsurpris-
ingly, we observed a discernible reduction in the
expression of AR when LNCaP were cultured in CSS as
opposed to FCS. Treatment with nutlin alone resulted in
a relatively small decrease in AR protein levels (Figure
2B) likely reflecting the decrease of its mRNA levels.
Greater reduction in AR protein occurred with concur-
rent nutlin and CSS treatment. This further reduction is
not accounted for by the decrease in transcription or
direct effect of elevated MDM2 on AR stability. This
change may result from a complex set of events induced
by activated p53 in an androgen-depleted milieu. Combi-
nation of nutlin and CSS enhaced the apoptotic response
in LNCaP and to a lesser extent in 22Rv1 cells in vitro.
(Figure 2). Presence of AR mutations in LNCaP and
22RV1 cells is likely responsible for the lack of robust in
vitro response to flutamide as reported previously
[38,41]. However, the second generation AR antagonist,
casidex, did show clear in vitro effect. The decrease in
AR protein levels appear to play a key role in the
enhanced apoptotic response since siRNA-mediated
knockdown of AR augmented apoptotic effect of nutlin
similar to the combination with CSS. The mechanism
behind the enhanced apoptosis in an AR-depleted envir-
onment is not entirely clear. One experimentally sup-
ported possibility is that AR activation attenuates p53-
dependent apoptotic signaling [41,44] and efficient
removal of AR expression leads to an overwhelming
response in favor of cell death and not just cellular arrest.
In vivo, the combination of androgen ablation with
nutlin treatment resulted in greater efficacy over corre-
sponding monotherapy arms in established LNCaP xeno-
grafts and was the only group to show complete
regressions in 7/20 mice despite the relatively high initial
tumor volume (400 mm
3). The greater degree of regres-
sion ultimately resulted in a dramatic increase of survival
rates for the combination (Figure 6C). Taken together our
data supports the notion that androgen withdrawal alone
fails to induce a durable apoptotic response thereby allow-
ing the eventual escape towards androgen independence.
Conclusions
The administration of nutlin with androgen deprivation
offers a novel two-pronged approach to cancer therapy
in which factors that sustain prostate tumor growth are
effectively removed with a simultaneous unleashing of
the powerful growth suppressive and pro-apoptotic
activity of p53. As increasingly more potent anti-andro-
gens are identified (e.g. abiraterone acetate and
MDV3100 [46]), their combination with MDM2 antago-
nists, currently in Phase I clinical development, could
offer a compelling strategy in future trials.
Methods
Cells, reagents and treatment
All cell lines used in this study were purchased from the
American Type Culture Collection (ATCC, Manassas,
VA) and grown in the recommended media supplemen-
ted with 10% heat-inactivated FBS (Invitrogen, Carlsbad,
CA) in a humidified environment with 5% CO2. Nutlin-
3a was synthesized at Hoffmann-La Roche Inc, (Nutley,
NJ). It was dissolved in DMSO and kept at -20°C as 10
mM stock solution. All other chemicals were purchased
from Sigma (St. Louis, MO). Hydroxy-flutamide was dis-
solved in ethanol and maintained at 4°C at 10 mM stock
concentration and used within 10 days. Bicalutamide
was dissolved in DMSO and kept at 4°C as a 10 mM
stock solution. MG132 was dissolved in DMSO and
kept at -20°C in 10 mM aliquots. Cells were treated
with 10 μM MG132 for 8 h prior to collection. For
experiments in charcoal stripped serum (CSS) cells were
washed with PBS and pre-incubated for 5 minutes in
phenol free media with 10% CSS, washed again and
replenished with phenol-free media containing 10% CSS
with or without compound. The LNCaP-MDM2 overex-
pressing line was generated using the human full length
MDM2 inserted into phCMV1 vector. The control is
the empty phCMV1 and the selection marker is G418 at
250 μg/ml.
Assays
Cell proliferation/viability was evaluated by the tetrazo-
lium dye (MTT) assay [47] as previously described [26].
For cell cycle analysis, LNCaP cells (1 × 10
6 cells/T75
flask) were incubated with 10 μM nutlin-3a for 24 h.
BrdU (20 μM; Sigma, St. Louis, MO) was added during
the last 1 h prior to fixation and cells were processed
and analyzed as previously described [27]. For apoptosis
assays, cells were seeded in 6-well tissue culture plates
at 2.5 × 10
5 (22Rv1 & DU145) or 5 × 10
5 (LNCaP) per
well and treated for 48 h or as indicated. The percen-
tage of Annexin V-positive cells was determined as
described [27]. For qRT-PCR analysis, cells were seeded
in 6-well plates, incubated overnight and treated with
DMSO or 10 μMn u t l i n - 3 af o r2 4h .T o t a lR N Aw a s
isolated and analyzed as described previously [28]. To
quantify microRNA expression, total RNA was isolated
using the TRIzol solution (Invitrogen) following
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Page 9 of 11manufacturer’s instruction. 10 ng of RNA was converted
to cDNA using the TaqMan
® microRNA Transcription
Kit and real-time PCR analysis was performed using
TaqMan
® microRNA assays (Applied Biosystems). For
Western blotting, cells were grown in 75 cm
2 flasks (10
6
cells per flask) or in duplicate in 6 well plates for siRNA
experiments, lysed in 0.1 -0.2 ml RIPA buffer and ana-
lyzed as previously described [27]. For siRNA experi-
ments, human-specific AR SMARTpool siRNAs and
non-targeting control siRNA were obtained from Dhar-
macon RNAi Technologies (Lafayette, CO) and used as
previously described [28].
Animals Studies
Precastrated male athymic nude mice (Crl:NU-Foxn1nu)
were obtained from Charles River Laboratories (Wil-
mington, DE) and cared for as previously described [27].
At 10 weeks of age, mice were implanted with a 12.5
mg sustained-release testosterone pellet (Innovative
Research of America, Sarasota, FL) 5 days before the
injection of tumor cells. A 1:1 mixture of human
LNCaP prostate cancer cells suspended in phenol-free
Matrigel and PBS were implanted in the right flank at a
concentration of 1 × 10
7 cells in 0.2 ml total volume.
The health of all animals was monitored daily by gross
observation and analyses of blood samples of sentinel
animals. All animal experiments were performed in
accordance with protocols approved by the Institutional
Animal Care and Use Committee in our AAALAC
accredited facility.
Four weeks after inoculation, mice were assigned to
different treatment groups with average tumor volume
approximately 400 mm
3. Mice were administered
Nutlin-3a at 200 mg/kg bid (n = 10) orally for 14 days
in 0.2 ml volume per injection or testosterone pellets
were removed under ketamine/xylazine cocktail
anesthesia to simulate androgen Ablation (AA) (n =
20). Other mice were treated with a combination of
AA + Nutlin-3a at 200 mg/kg bid orally for 14 days (n
= 20). Control mice were dosed with 0.2 ml vehicle
bid orally for 14 days + sham pellet removal under
ketamine/xylazine cocktail anesthesia. Tumor measure-
ments and weights were taken 2-3 times per week.
Tumor growth inhibition was calculated from percent
change in mean tumor volume compared to the con-
trol group. Average percent weight change was used as
a surrogate endpoint for tolerability in the experiment.
Five random mice in each group were bled via the ret-
rorbital sinus under anesthesia to obtain serum for
PSA determination using a PSA ELISA (American
Qualex, Inc., San Clemente, CA). Ten animals in each
group were continuously followed beyond the last day
of nutlin treatment to see if tumor re-growth would
occur. In this second phase of analysis, survival was
calculated using a cut-off individual tumor volume of
1000 mm
3 as a surrogate for mortality. The increase in
lifespan (ILS) was calculated as % using the formula:
[(Median day of death in treated tumor-bearing mice)
- (median day of death in control tumor-bearing
mice)] × 100 Median day of death in control tumor-
bearing mice. Statistical analysis was performed as pre-
viously described [27].
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